References

  1. Loma I, Heyman R. Multiple Sclerosis: Pathogenesis and Treatment. Curr Neuropharmacol 2011;9(3):409-416.
  2. McKay KA, Kwan V, Duggan T, Tremlett H. Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. Biomed Res Int. 2015;2015:817238.
  3. Fox RJ, Hersh CM. Multiple sclerosis. (2015) Available at: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/neurology/multiple_sclerosis/. Accessed: May 21, 2015.
  4. Disanto G, Morahan JM, Ramagopalan SV. Multiple sclerosis: risk factors and their interactions. CNS Neurol Disord Drug Targets. 2012;11(5):545-555.
  5. Pierrot-Deseilligny C, Souberbielle J-C. Is Hypovitaminosis D one of the Environmental Risk Factors for Multiple Sclerosis? Brain. 2010;133(7):1869-1888.
  6. Lucas RM, Hughes AM, Lay M-L J, et al. Epstein-Barr Virus and Multiple Sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(10):1142-1148.
  7. Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother. 2013;13(12 Suppl):3-9.
  8. Farrell RA, Antony D, Wall GR, et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology. 2009;73(1):32-38.
  9. Ramroodi N, Niazi AA, Sanadgol N, et al. Evaluation of reactive Epstein-Barr Virus (EBV) in Iranian patient with different subtypes of multiple sclerosis (MS). Braz J Infect Dis. 2013;17(2):156-163.
  10. Wingerchuk DM. Smoking: effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord. 2012 Jan; 5(1):13–22.
  11. Hernan M.A., Jick S.S., Logroscino G., Olek M.J., Ascherio A., Jick H., et al. (2005) Cigarette smoking and the progression of multiple sclerosis. Brain.128: 1461–1465.
  12. Manouchehrinia A, Tench CR, Maxted J, et al. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom  cohort study. Brain. 2013;136(Pt 7):2298-2304.
  13. Frederikson J, Crone V. Smoking: effects on the progression of multiple sclerosis—a cohort study of patients treated with immunomodulatory therapy. Neurology. 2015;84(14 Supplement):P2.222.
  14. Cortese M, Riise T, Bjørnevik K, et al. Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study. Mult Scler. 2015 May 6. [Epub ahead of print]
  15. Ben-Zacharia A. The relationship between body mass index (BMI) and multiple sclerosis progression. Neurology. 2015;84(14 Supplement):P2.212.
  16. Kavak KS, Teter BE, Hagemeier J, et al. Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. Mult Scler. 2014 Nov 12. [Epub ahead of print]
  17. Mielcarz DW, Kasper LH. The gut microbiome in multiple sclerosis. Curr Treat Options Neurol. 2015;17(4):344.
  18. Tankou S, Bry L, Gerber G, et al. Effect of vitamin D level in the gut microbiome of MS patients. Neurology. 2015;84(14 Supplement):P2.206.
  19. Sand HK, Baranzini S, Knight R, et al. The MS Microbiome Consortium (MSMC): an academic multi-disciplinary collaborative effort to elucidate the role of the gut microbiota in MS. Neurology. 2015;84(14 Supplement):P2.205.
  20. Tremlett H, Zhao Y, Devonshire V; UBC Neurologists. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol. 2009;256(3):374-381.
  21. Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of primary progressive multiple sclerosis. Neurology. 2009;73(23):1996-2002.
  22. Koch M, Kingwell E, Rieckmann P, et al. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81(9):1039-1043.
  23. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;15;83(3):278-286.